The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use after market launch.
Study 502.465(NCT00638911) was planned and conducted as 6 independent substudies with varying country participation. One study database, a data management plan or a TSAP were not planned and do not exist which precludes baseline and outcome analyses.
Study Type
OBSERVATIONAL
Enrollment
33,247
Primary Endpoints will be the change from baseline in mean systolic blood pressure.
Time frame: 4-24 Weeks
Secondary Endpoints are clinical control of the BP and response rate.
Time frame: 4-24 Weeks
Other secondary Endpoints will be discontinuations and tolerability.
Time frame: 4-24 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.